Identification and Validation of Serum CST1 as a Diagnostic Marker for Differentiating Early-Stage Non-Small Cell Lung Cancer from Pulmonary Benign Nodules.

Yanzhen LaiYu WangYaxian WuMeng WuShan XingYing XieShulin ChenXiaohui LiAo ZhangYi HeHuilan LiShuqin DaiJunye WangShudai LinYunmeng BaiHongli DuWan-Li Liu

Published in: Cancer control : journal of the Moffitt Cancer Center (2022)

Serum CST1 may serve as a novel diagnostic marker for differentiating early-stage NSCLC from PBN and HC, and could be used as a prognosis predictor in NSCLC patients.

Keyphrases

early stage
small cell lung cancer
end stage renal disease
ejection fraction
newly diagnosed
advanced non small cell lung cancer
peritoneal dialysis
squamous cell carcinoma
magnetic resonance imaging
patient reported outcomes
brain metastases
rectal cancer
patient reported
locally advanced